Important note: Information in this article was accurate in November 2006. The state of the art may have changed since the publication date.
HIV Treatment Bulletin - Vol. 7, No. 11/12, November/December 2006
Cipla has launched a new fixed dose combination pill called Viraday.
Viraday is a combination of three anti-HIV drugs efavirenz 600 mg, tenofovir 300 mg and emtricitabine 200mg (a generic equivalent of Atripla).
At retail price of 5,200 rupees a month, Viraday is a fraction of the wholesale international price of approximately US$ 1,100 (approximately 52,800 rupees) a month.
cipla2006-11-10
IB060711-19
©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.